Methods of treatment

1. A method of treating a patient in need thereof with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole,

comprising the steps of:

(a) stopping posaconazole treatment;

(b) delaying administering, for at least 9 days after stopping posaconazole treatment, a dose of the CYP3A4 substrate drug that the patient would have received based on the patient's age and condition if the patient had not been treated with posaconazole; and then

(c) administering the dose of the CYP3A4 substrate drug;

wherein the CYP3A4 substrate drug is selected from the group consisting of cariprazine, crizotinib, sunitinib, tolvaptan, acalabrutinib, ticagrelor, dabrafenib, vemurafenib, fluticasone propionate/salmeterol, and cabozantinib.

2. The method of claim 1 , wherein the delaying in step (b) is at least 10 days.

3. The method of claim 1 , wherein the delaying in step (b) is at least 12 days.

4. The method of claim 1 , wherein the delaying in step (b) is at least 14 days.

5. The method of claim 1 , wherein the delaying in step (b) is in the range of from 9-28 days.

6. The method of claim 1 , wherein the delaying in step (b) is in the range of from 9-42 days.

7. The method of claim 1 , wherein the delaying in step (b) is in the range of from 9-21 days.

8. The method of claim 1 , wherein the delaying in step (b) is in the range of from 14-28 days.

9. The method of claim 1 , wherein the patient is treated for a disease or condition selected from the group consisting of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test, gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, advanced renal cell carcinoma (RCC), adult patients at high risk of recurrent RCC following nephrectomy, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease, treatment of clinically significant hypervolemic and euvolemic hyponatremia, including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH), adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection, metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test, locally advanced or metastatic anaplastic thyroid cancer (ATC) in patients with BRAF V600E mutation and with no satisfactory locoregional treatment options, unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test, the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation, unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib, asthma in patients aged 4 years and older, airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease, metastatic medullary thyroid cancer (MTC), hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, and advanced renal cell carcinoma.

10. The method of claim 1 , wherein the delaying in step (b) is 9 days.

11. The method of claim 1 , wherein the delaying in step (b) is 10 days.

12. The method of claim 1 , wherein the delaying in step (b) is 11 days.

13. The method of claim 1 , wherein the delaying in step (b) is 12 days.

14. The method of claim 1 , wherein the delaying in step (b) is 13 days.

15. The method of claim 1 , wherein the delaying in step (b) is 14 days.